RT Journal Article
SR Electronic
T1 Acidity of expiratory aerosols controls the infectivity of airborne influenza virus and SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.14.22272134
DO 10.1101/2022.03.14.22272134
A1 Luo, Beiping
A1 Schaub, Aline
A1 Glas, Irina
A1 Klein, Liviana K.
A1 David, Shannon C.
A1 Bluvshtein, Nir
A1 Violaki, Kalliopi
A1 Motos, Ghislain
A1 Pohl, Marie
A1 Hugentobler, Walter
A1 Nenes, Athanasios
A1 Krieger, Ulrich K.
A1 Stertz, Silke
A1 Peter, Thomas
A1 Kohn, Tamar
YR 2022
UL http://medrxiv.org/content/early/2022/03/14/2022.03.14.22272134.abstract
AB Enveloped viruses are prone to inactivation when exposed to strong acidity levels characteristic of atmospheric aerosol. Yet, the acidity of expiratory aerosol particles and its effect on airborne virus persistence has not been examined. Here, we combine pH-dependent inactivation rates of influenza A virus and SARS-CoV-2 with microphysical properties of respiratory fluids under indoor conditions using a biophysical aerosol model. We find that particles exhaled into indoor air become mildly acidic (pH ≈ 4), rapidly inactivating influenza A virus within minutes, whereas SARS-CoV-2 requires days. If indoor air is enriched with non-hazardous levels of nitric acid, aerosol pH drops by up to 2 units, decreasing 99%-inactivation times for both viruses in small aerosol particles to below 30 seconds.Conversely, unintentional removal of volatile acids from indoor air by filtration may elevate pH and prolong airborne virus persistence. The overlooked role of aerosol pH has profound implications for virus transmission and mitigation strategies.One Sentence Summary Respiratory viruses are sensitive to aerosol pH, an unidentified factor in the mitigation of airborne virus transmissionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss National Science FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are either contained in the manuscript or will be made available upon acceptance of the manuscript